Integrate toxopheresis into your holistic concept.
We support you step by step.
Integrating toxopheresis: We guide you step by step.
Do you run a holistic practice and already offer a variety of therapies beyond conventional medicine? Then Toxopherese® could be the perfect detoxification solution for your practice.
Toxopherese® is an innovative method that directly addresses the root causes of diseases, making it an ideal addition to a holistic therapy concept. It enables you to support your patients even more comprehensively and achieve sustainable, improved results.
Learn more about Toxopherese® through exclusive testimonials on our social media channels. Our partners and their patients share their experiences and the benefits of this therapy.
Toxopherese is an advanced technique that helps your patients reduce inflammation by systematically cleansing the body. What makes it unique? Harmful substances are selectively removed while essential plasma components remain intact. More details can be found below.
Integrating Toxopherese into your holistic concept is the perfect complement to detoxification. And the best part: You are not alone – we support you every step of the way. Our services include training and observation sessions, technical instructions, and targeted marketing strategies to maximize the success of your treatment offerings. Rely on our expertise and let’s develop the best solutions for your patients and your practice together.
To strengthen our community, we offer:
Training Sessions: Benefit from hands-on training on Toxopherese, led by our experienced medical coordinator, Dr. Harald Burgard.
Observation Sessions: Gain first-hand experience of the therapy process.
Technical Support: A technician will assist you during the initial treatments, providing you and your team with in-depth device training.
Marketing Strategies: We offer extensive social media training to help you promote your treatment offerings effectively. We visit your practice, conduct interviews, and create professional reels that you can use for your marketing.
TV Broadcasts: Take advantage of the opportunity to be interviewed about Toxopherese on the QS24 television channel, showcasing your practice and expertise to a wider audience.
Laboratories: Rely on our collaboration with IMD Laboratory and Bremen Laboratory for the highest diagnostic standards.
Studies: We support you in conducting new, innovative studies related to Toxopherese.
Administrative Templates: Simplify your daily practice with professionally prepared administrative templates.
ASF Foundation Contact: A foundation has been established to facilitate access to apheresis for chronically ill individuals. This foundation is dedicated to providing financial support for affected patients and promoting Toxopherese as an effective treatment option.
Regular Meetings (Jour Fixe): Stay up to date! Our recurring meetings cover topics such as Toxopherese procedures, complementary therapies (e.g., autologous serum therapy and frequency chips), marketing strategies, and much more.
Anonymous Data Transfer: Utilize secure, anonymized data exchange to gain valuable insights and collaborate with other practitioners.
Conferences & Trade Shows: We showcase Toxopherese at renowned professional events, increasing awareness and accessibility.
Lectures: Share your knowledge and expertise with fellow professionals by giving engaging presentations at conferences and trade shows.
Toxopherese is not just an innovative detoxification method—it is also an opportunity to advance your practice. Together, we shape the future of therapy—for your patients and your success.
Toxopheresis does not involve plasma exchange, does not lead to significant loss of electrolytes or immune bodies, but is a gentle procedure that is very well tolerated and places minimal stress on the body.
It is used for:
– Environmental stressors
– Rheumatic diseases
– Lipid disorders
– Chronic inflammation
– Post-infection conditions (e.g. Lyme disease)
– Autoimmune diseases
BECAUSE TREATMENT IS ALWAYS “THERAPY FOR CURRENT COMPLAINTS” AND “PREVENTION FOR THE FUTURE” AT THE SAME TIME.
TOXOPHERESIS®
Main Areas of Application: Treatment of environmental medical stressors (chronic poisoning from combinations of minimal amounts of various substances such as paints, plant and insecticides, car exhausts, plasticizers, microplastics, silicone implants, harmful metals like lead, cadmium, mercury, aluminum, and more) with the aim of improving or even eliminating chronically latent poisonings, silent inflammations, sub-toxic substance combinations and their consequences (autoimmune diseases, digestive disorders, neurological damage, cardiovascular diseases, etc.).
Toxopheresis® helps the body eliminate harmful proteins and metabolic products (e.g., cholesterol, etc.) or toxic substances (so-called paraproteins, tumor-associated proteins, circulating immune complexes, complex infection toxins, pathoproteins, haptens) and restore the deregulated metabolism, inflammatory cascade, or immune system back to its natural balance (so-called metabolic/immune modulation).
fields of treatment
- Age-related Macular Degeneration – Dry form
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Ulcerative Colitis – Failure of chemotherapy and/or impending surgical bowel removal
- Diabetic Foot Syndrome with impending limb amputation due to failure of conservative and conventional surgical therapy
- Dilated Cardiomyopathy – Positive Beta-Receptor Antibody Test
- Eaton-Lambert Syndrome (tumor-associated neurological disorder)
- Disseminated Encephalitis (Multiple Sclerosis) – Failure of Interleukin-Alpha therapy or antibody formation against therapeutic Interleukin with progressive course
- Familial Heterozygous Hypercholesterolemia with failure/adverse effects of conservative therapy and/or premature and progressive atherosclerosis/heart attack/stroke/renal vascular involvement
- Familial Homozygous Hypercholesterolemia
- Focal Segmental Glomerulosclerosis of native kidneys or post-kidney transplant with nephrotic syndrome and/or severe hypertriglyceridemia, failure of chemotherapy/cholesterol synthesis inhibitor therapy, and rapid progression of kidney insufficiency (loss of kidney function)
- Glomerulonephritis (inflammatory kidney diseases) pathogenetically guided – failure and/or severe side effects of chemotherapy
- Guillain-Barré Syndrome – Chronic form/acute form
- Hemophilia (Bleeding disorder) with detection of antibodies against Factor-V
- Inhibitor Hemophilia (bleeding tendency) with detection of Factor V antibodies
- HLA Sensitization after kidney transplant
- IgM-associated Polyneuropathy (tumor-associated neurological disorder)
- Isolated Familial Lp(a) Hyperlipoproteinemia with premature atherosclerosis/heart attack/stroke/renal vascular involvement/inoperable arterial occlusive disease of the legs
- Cryoglobulinemic Vasculitis (autoimmune-related vascular inflammation due to cold proteins)
- Linear IgA Dermatosis
- Lupus Erythematosus with failure/severe side effects of chemotherapy
- Lupus Erythematosus with progressive kidney involvement (Glomerulonephritis)
- Macular Degeneration (Adult form) – Dry form
- Behçet’s Disease – Failure and/or severe side effects of chemotherapy
- Raynaud’s Disease – Failure of conservative therapy
- Refsum’s Disease (Storage disease)
- Multiple Sclerosis (see also Disseminated Encephalitis)
- Necrobiotic Xanthogranulomatosis (with paraprotein)
- Nephrotic Syndrome in inflammatory kidney diseases (Glomerulonephritis) pathogenetically guided – Failure and/or severe side effects of chemotherapy
- Pemphigus Foliaceus – Failure and/or severe side effects of chemotherapy
- Pemphigus Vulgaris – Failure and/or severe side effects of chemotherapy
- Peripheral Arterial Occlusive Disease (pathogenetically guided) with failure of conservative and conventional surgical therapy options and impending limb loss
- Polymyositis – Failure and/or severe side effects of chemotherapy
- Retinitis Pigmentosa in Refsum’s Disease
- Rheumatoid Arthritis – Failure of chemotherapy and extreme progression
- Systemic Progressive Scleroderma with kidney involvement (Glomerulonephritis)
- Scleromyxedema Arndt-Gottron – with kidney involvement and detection of paraprotein – Failure and/or severe side effects of chemotherapy
- Stiff-Man Syndrome
- Thromboangiitis Obliterans (Alternative to amputation)
- Transplant Vasculopathy after heart transplantation
- Xanthogranulomatosis (Necrobiotic) with paraprotein
Additionally, there are innovative treatment fields for Toxopheresis®.
Beratungtreatment fields
- Aerotoxic Syndrome (Pathogenesis see below)
- Alzheimer’s Dementia Syndrome (Pathogenesis see below)
- Burden of heavy metals, solvents, and other environmental toxins leading to severe diseases in the areas of autoimmune diseases and/or neurological diseases and/or skin diseases (e.g., Aerotoxic Syndrome, Fibromyalgia: blistering skin diseases, toxic nerve damage, kidney damage, MCS, CFS, Ciguatera poisoning, Parkinson’s and Dementia syndromes)
- Borrelia as late-stage Borrelia with severe disease courses that are no longer manageable by conventional means (CFS/ Guillain-Barré Syndrome resistant to immunoglobulin therapy/ severe therapy-resistant autoimmune diseases such as rheumatoid arthritis, systemic connective tissue diseases, lupus diseases, cardiomyopathies based on proven autoantibodies against the heart in Borrelia infection)
- Chronic Fatigue Syndrome (CFS)
- Chronic Hepatitis C (covered by insurance in Japan)
- Fibromyalgia Syndrome
- Hyperbilirubinemia in severe congenital metabolic liver diseases with impending brain damage
- Hypertension (high blood pressure) with alpha1 and/or Angiotensin 1 antibody positive test – no or only poor treatability with conventional pharmacotherapy
- Multiple Chemical Sensitivity Syndrome (MCS)
- Multiple Sclerosis (according to the study of the Canadian-American Apheresis Society)
- Myalgic Encephalomyelitis (ME)
- Post Vaccination Syndrome
The field of application is extremely versatile and continues to expand. Through targeted application, our partners directly address the cause with their treatment offer and support the body in its natural regeneration.
Beratung– Therapeutic plasma exchange (plasmapheresis)
– Double-filtration plasmapheresis
– Selective apheresis
– Double-filtration plasmapheresis and adsorption
– Hemoperfusion
AFERsmart Plus & AFERsmart
AFERsmart Plus™ is a therapeutic apheresis device capable of performing various treatments: plasmapheresis, double cascade filtration, double-filtration adsorption plasma filtration, and hemoperfusion. The device can perform both heparin and citrate treatments, and allows for inline control of plasma flow. It can also be integrated with an external heater (Kalos).
The AFERsmart™ is a versatile therapeutic apheresis device offering various treatment options: hemoperfusion, therapeutic plasma exchange, double-filtration lipid apheresis, as well as rheopheresis and selective apheresis. The device also supports double-filtration/rheopheresis with adsorption and offers the possibility of integration with an external heater (e.g., Kalos).
Technology
– Air-free pressure transducers (Type DOME)
– Pre-assembled tubing kit
– Three peristaltic pumps
– One syringe pump
– Double scale
– Heparin and/or citrate anticoagulant
– Proprietary self-adjusting clamp for controlling plasma flow (plasmapheresis)
– Automatic flushing procedure for the plasmapheresis filter
– KALOS heater for blood/replacement fluid (optional)
– External console (optional)
The double-filtration treatment can be used to remove various molecules that can be classified as follows:
– Antibodies
– Pathogenic substances
– Metabolic factors (e.g., LDL)
– Inflammatory mediators
Toxopheresis is a highly innovative medical procedure for…
– Removing toxins, inflammatory mediators, and malformed autoantibodies from the blood.
– Immune modulation in chronic and acute diseases of metabolism and the immune system (so-called autoimmune diseases).
– Treatment of environmental medical stressors. These have been increasing worldwide in recent years and affect us all. Whether PFAS from Teflon pans, pesticides from fruits/vegetables, microplastics from drinking water, car exhausts from the air, heavy metals such as lead, cadmium, or mercury from industrial emissions/fish/combustion residues, etc., every person is affected today. When, for example, detoxification enzymes are insufficiently working, one can quickly fall out of balance and become ill.
– Improvement of rheology (blood flowability) through the removal of pathological proteins from the plasma that negatively alter circulation.
Harmful substances such as environmental toxins, heavy metals, inflammatory mediators, immune complexes, and other toxic substances are selectively filtered out of the blood and accumulate in the eluate. If desired, the eluate can be analyzed in the Bremen laboratory. An example image of eluates is shown here:
Our most commonly used filters: Versatile-PES® & SELECTI 2.0
Plasma filter Versatile-PES®
Versatile-PES® is a hollow fiber membrane specifically designed for plasma separation. It is a polyethersulfone membrane used in plasmapheresis and blood donation.
The asymmetric structure of the Versatile®-PES offers excellent filtration properties.
The Versatile-PES® membrane was developed to achieve the following properties:
– Optimized diameter and wall thickness to ensure remarkable mechanical strength of the fiber and the highest filter surface area with minimal space requirements.
– Very smooth inner membrane surface, which causes less damage to red blood cells in the bloodstream and minimizes the risk of hemolysis.
– Excellent separation performance, measured by the permeability of plasma proteins through the membrane (over 90%).
– Optimized membrane cutoff, allowing the use of a significant TMP (transmembrane pressure) value.
Filter: SELECTI 2.0
The plasma fractionators are non-active medical devices designed to remove high molecular weight molecules (e.g., viruses, autoantibodies, immune complexes, LDL, etc.) from the plasma. These molecules are responsible for various pathological clinical pictures and are removed from the plasma, which has previously been separated from the cellular blood component by plasmapheresis.
The plasma fractionator selectively removes pathogenic substances from the plasma after an initial step where the plasma is separated from the whole blood using a plasma filter. These substances typically have a higher molecular weight than the fractionator’s cutoff and are therefore retained in the device, while all proteins with a lower molecular weight and plasma water pass through the fractionator and are returned to the patient. This mechanism minimizes the need to return replacement fluids and plasma proteins to the patient: it is rarely necessary to substitute albumin during the procedure.
Note: Our portfolio includes various filters that can be used.
